Ireland - English - HPRA (Health Products Regulatory Authority)

fannin (uk) ltd - salmeterol - pressurised inhalation, suspension - 25 microgram(s) - selective beta-2-adrenoreceptor agonists; salmeterol

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Ireland - English - HPRA (Health Products Regulatory Authority)

fannin limited - salmeterol - pressurised inhalation, suspension - 25 microgram(s) - selective beta-2-adrenoreceptor agonists; salmeterol

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - salmeterol as xinafoate - powder for inhalation - salmeterol as xinafoate 50 mcg - salmeterol - salmeterol - salmeterol is a selective beta-2-agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (copd).in asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 100 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/500 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/250 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

European Union - English - EMA (European Medicines Agency)

teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - airexar spiromax is indicated for use in adults aged 18 years and older only.asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.chronic obstructive pulmonary disease (copd)airexar spiromax is indicated for the symptomatic treatment of patients with copd, with a fev1

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.